Benchmark announces 'major step forward' in combating tilapia disease

(07/12/19)

Streptococcus infections are among the most critical disease challenges in tilapia production and this technological breakthrough presents a significant opportunity for the industry to reduce streptococcus infections and the use of antibiotic treatments.

Benchmark’s genomic analysis from controlled disease resistance trials has shown that a significant proportion of the genetic variation for resistance is caused by a small region of DNA – a Quantitative Trait Locus or QTL.

Benchmark has made a patent application................................................


Click here to read the rest of this article:
https://fis.com/fis/worldnews/